newsfilter
← Latest News
Business Wire·

Sesen Bio Announces Productive CMC Type A Meeting with the FDA

Vicineum™ manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patient